glp-1 news past 3 days GLP-1 obesity drugs and eating disorders are not well understood yet : NPR Side Effects: Endocrine Society Journals

They were sued in August 2023 by a Louisiana woman Jaclyn Bjorklund, who alleged the companies downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro, and in particular played down the risk of gastroparesis, which is the slowing or stopping of the digestive system

By contrast, BACH1 knockdown reduced the BPC-157-associated CCK-8 signals, tube-like network formation, and expression of several angiogenesis-related factors

You may notice less GI discomfort around meals, though individual responses vary.*

However, most patients experience: Early Stage (First Few Sessions) Subtle glow Improved hydration appearance Reduced dullness Progressive Stage Brighter complexion More even skin tone Fading of mild pigmentation After Full Treatment Course Refined skin clarity Healthier, luminous appearance Reduced oxidative stress impact Its important to maintain realistic expectations

For obesity treatment, it is not covered by insurance and is self-pay